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SUMMARY
Objective: To understand the current burden of focal epilepsy (FE) as a function of sei-
zure frequency.
Methods: Patients were identified from the United States (2011, 2012, and 2013), five
European countries (EU; France, Germany, Italy, Spain, United Kingdom) (2011 and
2013), and Brazil (2011 and 2012) National Health and Wellness Survey (NHWS), a
nationally representative, Internet-based survey of adults (18+ years). TheNHWS col-
lected data on respondents’ quality of life (QoL), health utilities, productivity loss, and
healthcare resource utilization. Indirect and direct costs were calculated from the lit-
erature. Altogether, 345 of 176,093 (U.S.A.), 73 of 30,000 (United Kingdom), 53 of
30,001 (Germany), 53 of 30,000 (France), 41 of 12,011 (Spain), 37 of 17,500 (Italy), and
71 of 24,000 (Brazil) respondents self-reported a diagnosis of FE.
Results: Many respondents (U.S.A.: 56.2%; 5EU: 41.6%; Brazil + 5EU: 40.5%) reported
persistent seizures (≥1 per year). Over 60% to just over 71% of respondents with FE
were treated with antiepileptic drugs (AEDs). In the United States, seizure frequency
was associated with hospitalizations, indirect costs (ages 18–60), and total direct costs.
For the 5EU and Brazil + 5EU, seizure frequency was associated with physical QoL,
health utilities, activity impairment, and emergency room (ER) visits. Additional asso-
ciations were observed for the 5EU on hospitalizations, indirect costs (ages 18–60), ER
visit costs, and total direct costs and for Brazil + 5EU on absenteeism, overall work
impairment, and provider visits. Costing was not performed for Brazil + 5EU.
Significance: Around half of the patients had persistent seizures despite most taking
an AED in this 2011–2013 dataset. The results support the hypothesis that reducing
seizures can improve productivity and reduce resource utilization and associated
costs. Regional differences may reflect differences in healthcare systems and selected
patient populations. Overall, the results suggest that additional treatment options are
needed to improve seizure control and reduce related costs.
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The objective of this study is to provide recent data in
adult, focal-onset epilepsy (FE) patients regarding the rela-
tionship between seizure frequency and health outcomes
(quality of life [QoL; including health utilities], productiv-
ity, indirect costs, healthcare resource utilization [HRU],
and direct costs) in multiple Western populations where
pharmacoeconomic modeling is required by reimbursement
decision makers and these data are useful as model inputs.
Focal epilepsy comprises about 55.7–61.1% of the over-
all epilepsy patient population.1,2 Whereas multiple studies
have evaluated the relationship between seizure frequency
and QoL,3 most have done so in the overall adult epilepsy
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population or the population with temporal lobe epilepsy,3
and few have evaluated FE as a whole.4 Few data regarding
a specific type of QoL known as a health utility are available
for FE. Health utilities are a key parameter in economic
evaluations.
No recent studies (since 2000) of the effect of seizure fre-
quency on productivity or indirect costs were identified. A
2009 study of Chinese patients reported indirect costs by
nonnumerical approximations of seizure frequency: seizure
remission, occasional seizures, active non-drug-resistant
epilepsy, and drug-resistant epilepsy.5
Few studies have examined direct costs by seizure fre-
quency.6–9 Most previous studies did not present data
among FE patients by seizure frequency. Hence, current
knowledge about how seizure frequency influences both
indirect and direct costs among FE patients is limited.
Methods
Dataset and sample selection
The National Health and Wellness Survey (NHWS;
www.kantarhealth.com) is a self-administered, cross-
sectional general health survey of adults (aged 18 and older)
in the United States (U.S.), five European Union countries
(5EU; United Kingdom, Germany, France, Italy, and Spain),
Brazil, China, Japan, and Russia. The NHWS is not an epi-
lepsy-specific survey. This study focused on the U.S., 5EU,
and Brazil datasets because of the pharmacoeconomic data
requirements in these countries. The survey was initially
translated from the original U.S. English to Germany Ger-
man, France French, Italy Italian, Spain Spanish, and Brazil
Portuguese by Transperfect (certified to ISO 9001:2008 and
EN 15038:2006 standards). The U.S. English version was
utilized in the United Kingdom. These translations were
then reviewed and edited by Absolute Translations (certified
to ISO 9001 standards), returned to Transperfect for further
review and editing, tested with potential respondents, and
further revised to obtain final versions.
Potential survey participants were identified using Light-
speed Research, a market research company, and its
affiliates, who maintain a survey community that has agreed
to receive invitations to participate in online surveys.
Unique members are verified through their Internet Protocol
addresses, and participants are limited to 12 surveys per
year. In each country, a stratified random sampling frame-
work was utilized to match potential respondents on age and
gender to the distributions of the country. U.S. demographic
distributions were obtained from the U.S. Census Bureau,
and for all other countries, from the International Database
of the U.S. Census Bureau. Additional stratifications for
race/ethnicity distributions were performed for the United
States. Additional details regarding data collection and sam-
pling procedures are available from a similar companion
study for idiopathic generalized epilepsy.10 The NHWS
study protocol was approved by Essex IRB (Lebanon, NJ,
U.S.A.). Informed consent was obtained from all partici-
pants, and participants’ privacy rights were observed at all
times.
Data from multiple years (U.S.: 2011, 2012, and 2013;
five European countries [5EU; France, Germany, Italy,
Spain, and the United Kingdom]: 2011 and 2013 (5EU data
not fielded in 2012); and Brazil: 2011 and 2012) were
included in this analysis. Response rates for the NHWS in
each region and year were as follows:
U.S.: 13.10% (2011; 572,738 invited), 7.24% (2012;
1,035,617 invited), and 6.34% (2013; 1,183,287 invited)
5EU: 17.22% (2011): 18.22% (France; 82,320 invited),
17.30% (Germany; 86,728 invited), 25.09% (Italy;
29,895 invited), 21.78% (Spain; 23,007 invited), and
13.40% (United Kingdom; 111,948 invited)
15.65% (2013): 18.6% (France; 80,619 invited), 14.06%
(Germany; 106,685 invited), 16.00% (Italy; 62,499
invited), 14.57% (Spain; 48,036 invited), and 15.26%
(United Kingdom; 98,284 invited)
Brazil: 4.17% (2011; 287,699 invited) and 4.00% (2012;
300,247 invited)
Participants were included in the current study if they
self-reported a diagnosis of FE (responded to: “What type of
epilepsy have you been diagnosed with?” and selected
“Symptomatic Partial Epilepsy [Focal epilepsy, Temporal
lobe epilepsy, Frontal lobe epilepsy]” or “Idiopathic Partial
Epilepsy [Benign Focal Epilepsy of Childhood/BFEC]”).
On the basis of affirmative responses to the aforementioned
item, the study included final deduped FE sample sizes of
n = 345 of 176,093 who completed the NHWS (2011–2013
U.S.), n = 257 (2011 and 2013 5EU: n = 73 of 30,000 [Uni-
ted Kingdom], n = 53 of 30,001 [Germany], n = 53 of
30,000 [France], n = 41 of 12,011 [Spain], and n = 37 of
17,500 [Italy]), and n = 71 of 24,000 (2011 and 2012 Bra-
zil). Although most BFEC patients’ seizures will remit prior
to adulthood, these patients were included in the analysis
because a disproportionally high number of respondents
selected idiopathic partial epilepsy, indicating that patients
possibly had difficulty distinguishing between symptomatic
and idiopathic epilepsy. The full list of response options
Key Points
• The burden of focal epilepsy (FE) by seizure fre-
quency was examined
• Quality of life and costs were assessed for FE patients
in the United States, EU, and Brazil
• Up to 56% of patients reported experiencing one or
more seizures per year
• As seizure frequency increased, productivity
decreased and costs increased
• Regional differences were observed on the exact out-
comes associated with seizure frequency
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was: “Idiopathic Generalized Epilepsy (Myoclonic seizures,
Absence seizures, or Grand Mal seizures),” “Idiopathic Par-
tial Epilepsy (Benign Focal Epilepsy of Childhood/BFEC),”
“Symptomatic Generalized Epilepsy (West syndrome, Len-
nox-Gastaut syndrome),” “Symptomatic Partial Epilepsy
(Focal Epilepsy, Temporal lobe epilepsy, Frontal lobe epi-
lepsy),” and “Don’t know.” All options were mutually
exclusive, and respondents could choose only one.
Measures
Seizure frequency
The NHWS asked respondents: “How often do you expe-
rience a seizure (more than once a week, once a week, two
or three times a month, once a month, every 3 months,
every 6 months, once a year, or less than once a year)?” The
primary independent variable (seizure frequency categories:
once a week or more, 1–3 times a month, 1–4 times a year,
and less than once a year) was created from these response
options.
Health and economic outcomes
QoL was measured by the Short Form (mix of SF-12v2
and SF-36v2) questionnaire. The Physical Component Sum-
mary (PCS) and Mental Component Summary (MCS)
scores and health utility (SF-6D) scores are reported here.
Productivity was measured by the Work Productivity and
Activity Impairment—General Health (WPAI-GH) ques-
tionnaire. HRU was assessed by asking participants to
report the number of healthcare provider visits, emergency
room (ER) visits, and hospitalizations they had in the prior
6 months for their medical condition. The results reported
here are prorated to 1 year. Indirect costs were calculated
from these productivity measures using wage data for each
country (U.S. and 5EU) and excluded patients who were not
employed. In addition to this variable, another indirect cost
variable that factored in unemployment as 100% absen-
teeism was created for patients ages 18–60. Further details
on these measures, patient demographics, health character-
istics, health outcomes, and costing methods are available in
the companion study publication.10
Statistical analyses
Unadjusted analyses
Unadjusted analyses of the association between seizure
frequency and health outcomes (MCS, PCS, health utilities,
productivity [absenteeism, presenteeism, overall work
impairment, and activity impairment], indirect costs, HRU
[physician visits, ER visits, and hospitalizations], and direct
costs) were conducted using chi-square tests for categorical
variables and analysis of variance (ANOVA) tests for con-
tinuous variables for each region (U.S., 5EU, and
Brazil + 5EU). A Bonferroni-adjusted threshold was
applied to adjust for the repetitions of global tests across the
three datasets, and a p < 0.01667 was considered significant
and marked with two asterisks in Table 3.
Adjusted analyses
Adjusted analyses of the association between seizure fre-
quency and health and economic outcomes were performed
by adding covariates from a two-phase confounder selection
process. Phase 1 of the confounder selection process
involved selecting covariates (demographic and health char-
acteristic variables) that were associated (p < 0.20) with
seizure frequency based on the unadjusted results. Phase 2
involved assessing generalized linear models (GLMs) to
further reduce the covariate list by selecting the covariates
that were associated (p < 0.20) with each outcome variable
among patients in the seizure frequency reference group.11
For phase 2, separate multivariable GLMs were created
for the following dependent variables for the U.S. and 5EU
datasets: MCS, PCS, health utilities, activity impairment,
indirect costs, and direct costs. Covariates selected for the
indirect cost models were utilized for the models of absen-
teeism, presenteeism, and overall work productivity.
Covariates selected for the direct cost model were utilized
for the models of the individual components of HRU.
Because costing will not be performed for the Brazil + 5EU
dataset, separate GLMs were created for all dependent vari-
ables.
The final adjusted analyses were performed for each
health and economic outcome variable using a GLM in the
total subject population with the following as independent
variables: seizure frequency, age, gender, and variables with
a p < 0.20 in phase 2 of the confounder selection process.
GLMs for QoL outcomes utilized a normal distribution
with an identity link function. GLMs for productivity, activ-
ity impairment, HRU, and costs utilized a log link function
and a negative binomial distribution. Standard errors were
automatically adjusted for model dispersion.
Adjusted means were reported for each seizure fre-
quency group using a maximum likelihood algorithm.
Additionally, all the GLMs from the final adjusted analy-
ses were re-run with the same exact set of covariates
with seizure frequency treated as a continuous variable.
The omnibus p values are reported for these models.
Where seizure frequency (continuous variable) was asso-
ciated with a given health outcome in the adjusted
model, subsequent pairwise multiple comparisons were
conducted: (1) between the lowest seizure frequency
group (<1 seizure/year) and all other categories and (2)
between the highest seizure frequency group (≥1 sei-
zures/week) and all other categories. Bonferroni-adjusted
thresholds were applied to p values in Table 4: (1) glo-
bal tests were significant if p < 0.01667 given their repe-
tition across three datasets and were marked with two
asterisks; and (2) the five unique pairwise tests were sig-
nificant if p < 0.01 and were marked with three aster-
isks.
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Special considerations for the Brazilian dataset
Owing to the small sample size of the Brazilian dataset
(n = 71), the Brazil and 5EU samples were compared on
demographics and health characteristics to evaluate whether
it would be reasonable to combine the two datasets for the
purpose of estimating Brazilian outcomes (Table 1). A two-
tailed p < 0.05 was considered statistically significant.
Because minimal differences were identified, the above
multivariable analyses were conducted for Brazil using a
combined Brazil + 5EU dataset. However, because some
differences were observed, the covariate selection process
was performed separately for the Brazil + 5EU dataset
rather than using the covariates selected for the 5EU dataset.
No costing was performed on this combined dataset.
Results
The proportions reporting focal epilepsy out of the epi-
lepsy patients were 21% U.S., 20% United Kingdom, 18%
Germany, 22% France, 36% Spain, 41% Italy, and 41%Bra-
zil.
Table 1 demonstrates the similarities between the 5EU
and Brazil datasets on patient characteristics and outcomes.
Patient characteristics appeared to be qualitatively different
between the U.S. and other datasets (5EU, Brazil + 5EU)
on certain estimates (Table 2). The distribution of seizure
frequencies for the U.S. dataset appears flatter (15.9%,
19.7%, 20.6%, 43.8%) than do the distributions for the 5EU
(9.3%, 9.7%, 22.6%, 58.4%) and Brazil + 5EU (8.5%,
9.8%, 22.3%, 59.5%) datasets. Regarding epilepsy charac-
teristics, the U.S. dataset had at least 9% more patients
reporting epilepsy duration of more than 30 years, at least
7% more reporting current AED use, and more patients
reporting use of two or more AEDs. The proportion of
patients with persistent seizures (>1 per year) among AED
users was higher in the U.S. (66.4%) than the 5EU (53.0%)
and Brazil + 5EU (52.3%) datasets (data not reported in
tables). Individual AED use varied somewhat between
regions (Table 2).
Unadjusted analyses by seizure frequency
Unadjusted analyses examining the relationship between
seizure frequency and outcomes demonstrated statistically
significant associations between seizure frequency and almost
all evaluated outcomes for the 5EU (except provider visits)
and Brazil + 5EU datasets. In the U.S. dataset, less than half
of tested associations were statistically significant. Significant
associations were observed for MCS, health utility, presen-
teeism, activity impairment, provider visits, total indirect
costs, and total direct costs with seizure frequency (Table 3).
Adjusted analyses, including pairwise comparisons
between seizure frequency categories
In the adjusted analyses for the U.S. dataset, seizure fre-
quency was statistically significantly associated with MCS,
presenteeism, overall work impairment, hospitalizations,
total indirect costs, total indirect costs (ages 18–60), hospi-
talization costs, and total direct costs (Table 4). Pairwise
comparisons, however, met Bonferroni thresholds for dif-
ferences between the highest and lowest seizure frequency
groups only for hospitalizations, indirect costs (ages 18–
60), and direct costs.
It should be noted that differences between the two
highest seizure frequency groups compared with the lowest
seizure frequency group on the MCS met the minimally
important difference (MID) threshold of 3.12 Average total
indirect costs (ages 18–60) were approximately $8,500
higher per person per year with one or more overall seizures
per week compared to the reference group. Average total
direct medical costs were $25,000 more per patient per year
for patients with one or more overall seizures per week com-
pared to the reference group (Table 4).
For the 5EU dataset, seizure frequency continued to be
statistically significant for most outcomes after adjustments,
with the exception of provider visits, presenteeism costs,
and hospitalization costs (Table 4). Pairwise comparisons
supported global associations for PCS, health utilities, activ-
ity impairment, ER visits, hospitalizations, indirect costs
(ages 18–60), ER visit costs, and total direct costs.
All statistically significant differences on the MCS, PCS,
and health utilities met their respective MID thresholds (3
for MCS, PCS and 0.041 for health utilities).12,13 Total indi-
rect costs (ages 18–60) were about 6,200 EUR more per
patient per year for the highest seizure frequency group
compared with the lowest. ER visit costs were about 180
EUR more per patient per year for the highest seizure fre-
quency group compared with the lowest. Total direct medi-
cal costs were 1,200 EUR higher per patient per year for the
highest seizure frequency group compared with the lowest
(Table 4).
In the Brazil + 5EU adjusted analyses, seizure frequency
was statistically significantly associated with all outcomes
(Table 4). The results of the pairwise comparisons were
similar to those of the 5EU dataset with the exception of
absenteeism, overall work impairment, and provider visits.
For this dataset, both of the two highest seizure frequency
groups reached the Bonferroni threshold (p < 0.01) when
comparing against the lowest seizure frequency group on
PCS, health utilities, absenteeism, and activity impairment.
Overall work impairment, provider visits, and ER visits
reached the Bonferroni threshold in showing a difference
between the highest and lowest seizure frequency groups.
Statistically significant differences on the MCS, PCS, and
health utilities met their respective MID thresholds (3 for
MCS, PCS and 0.041 for health utilities).12,13
Discussion
The NHWS self-reported epilepsy prevalence is fairly
close to physician-diagnosed values in the literature
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(NHWS vs. NHWS sans “Don’t Know” vs. literature [per
1,000]: U.S. 9.1 vs. 6.5 vs. 7.1, United Kingdom 12.2 vs. 8.3
vs. 8.6, Germany 10.0 vs. 5.4 vs. 9.1, France 8.2 vs. 5.0 vs.
5.4, Spain 9.5 vs. 6.2 vs. 4.8, Italy 5.2 vs. 3.7 vs. 4.6, and
Brazil 7.3 vs. 4.5 vs. 10.7).1,14–19 This is consistent with
studies that indicate that self-reporting in epilepsy is
typically reliable.20
Publications from physician-diagnosed, epilepsy studies
report that FE comprises 61.1% and 55.7% of the total
epilepsy population.1,2 Among patients who knew their sei-
zure type and etiology (i.e., removing the Don’t Know
patients), 30% (U.S.), 29% (United Kingdom), 33% (Ger-
many), 36% (France), 55% (Spain), 57% (Italy), and 66%
(Brazil) reported FE. Because the overall epilepsy estimates
are close to the literature, it is possible that some FE patients
with secondarily generalized seizures (SGSs) classified
themselves as idiopathic generalized epilepsy (IGE) or
“Don’t Know.” The proportions reporting IGE out of the
Table 1. Evaluation of whether 5EU and Brazilian data can be combined for FE
Total (N = 328) 5EU FE (N = 257) Brazil FE (N = 71) p Value
Age (years)—mean  SD 42.61  14.00 44.14  14.30 37.10  11.33 <0.001
Female (%) 159 (48.48) 125 (48.64) 34 (47.89) 0.911
Married/living with partner (%) 193 (58.84) 149 (57.98) 44 (61.97) 0.545
College educated (%) 117 (35.67) 81 (31.52) 36 (50.70) 0.003
Employed (%) 195 (59.45) 143 (55.64) 52 (73.24) 0.008
Retired (%) 40 (12.20) 35 (13.62) 5 (7.04) 0.134
Long-term disability (%) 24 (7.32) 23 (8.95) 1 (1.41) 0.031
Body mass index
Underweight (%) 15 (4.57) 10 (3.89) 5 (7.04) 0.712
Normal weight (%) 141 (42.99) 109 (42.41) 32 (45.07)
Overweight (%) 101 (30.79) 81 (31.52) 20 (28.17)
Obese (%) 69 (21.04) 55 (21.40) 14 (19.72)
Decline to provide weight (%) 2 (0.61) 2 (0.78) 0 (0.00)
Drink alcohol (%) 217 (66.16) 175 (68.09) 42 (59.15) 0.159
Smoking behavior
Nonsmoker (%) 144 (43.90) 111 (43.19) 33 (46.48) 0.258
Former smoker (%) 95 (28.96) 71 (27.63) 24 (33.80)
Current smoker (%) 89 (27.13) 75 (29.18) 14 (19.72)
Exercise (%) 193 (58.84) 155 (60.31) 38 (53.52) 0.303
Charlson comorbidity index—mean  SD 0.85  2.30 0.82  2.39 0.97  1.99 0.626
Length of time diagnosed with epilepsy
0–5 years (%) 58 (17.68) 49 (19.07) 9 (12.68) 0.827
6–10 years (%) 35 (10.67) 32 (12.45) 3 (4.23)
11–15 years (%) 48 (14.63) 35 (13.62) 13 (18.31)
16–19 years (%) 22 (6.71) 18 (7.00) 4 (5.63)
20–30 years (%) 73 (22.26) 53 (20.62) 20 (28.17)
31 years or greater (%) 92 (28.05) 70 (27.24) 22 (30.99)
Using a prescription medication of epilepsy (%) 199 (60.67) 166 (64.59) 33 (46.48) 0.006
Total number of epilepsy prescriptions
None (%) 129 (39.33) 91 (35.41) 38 (53.52) 0.016
One medication (%) 137 (41.77) 115 (44.75) 22 (30.99)
Twomedications (%) 42 (12.80) 37 (14.40) 5 (7.04)
Three or more medications (%) 20 (6.10) 14 (5.45) 6 (8.45)
MCS—mean  SD 41.79  11.06 41.60  11.12 42.48  10.91 0.554
PCS—mean  SD 46.95  9.86 46.62  10.26 48.16  8.21 0.244
Health utility—mean  SD 0.65  0.13 0.66  0.13 0.64  0.11 0.256
Absenteeisma,b (%)—mean  SD 8.16  20.75 7.80  20.51 9.16  21.60 0.693
Presenteeisma,b (%)—mean  SD 26.01  28.96 26.34  29.21 25.10  28.51 0.798
Overall work impairmenta,b (%)—mean  SD 30.28  32.46 30.68  32.76 29.14  31.90 0.776
Activity impairmentb (%)—mean  SD 34.09  31.88 36.34  32.49 25.92  28.31 0.014
Healthcare provider visits in past 6—mean  SDmonths 7.69  8.15 7.69  8.36 7.68  7.41 0.988
ER visits in the past 6 months—mean  SD 0.53  1.19 0.42  0.95 0.93  1.75 0.001
Hospitalizations in the past 6 months—mean  SD 0.29  0.69 0.27  0.64 0.37  0.83 0.288
ER, emergency room; FE, focal epilepsy; MCS, Mental Component Summary; PCS, Physical Component Summary; SD, standard deviation.
Overall p values are provided indicating at least one group is different from another. Lower scores on MCS, PCS, and health utilities indicate a decrease in quality
of life. Absenteeism, presenteeism, overall work impairment, and activity impairment scores represent impairment percentages, with higher scores indicating
greater impairment (0–100%).
aIncludes only employed respondents.
bProductivity measures are derived from theWork Productivity and Activity Impairment (WPAI).
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Table 2. Patient characteristics for FE
U.S. values (N = 345) 5EU values (N = 257) Brazil + 5EU values (N = 328)
Age (years)—mean  SD 46.63  15.17 44.14  14.30 42.61  14.00
Female (%) 185 (53.62) 125 (48.64) 159 (48.48)
Race/ethnicity
Non-Hispanic white (%) 268 (77.68) N/A N/A
Non-Hispanic black (%) 24 (6.96) N/A N/A
Hispanic (%) 24 (6.96) N/A N/A
Other ethnicity (%) 29 (8.41) N/A N/A
Married/living with partner (%) 182 (52.75) 149 (57.98) 193 (58.84)
College educated (%) 135 (39.13) 81 (31.52) 117 (35.67)
Annual household income
<$25K, <€20K/<£20K, <R$ 1,000 (%) 107 (31.01) 90 (35.02) 101 (30.79)
$25K–<$50K, €20–<50K/£20–<40K, R$ 1,001–R$ 6,500 (%) 107 (31.01) 106 (41.25) 132 (40.24)
$50K–<$75K, €50K+/£40K+, R$ 6,501+ (%) 57 (16.52) 34 (13.23) 62 (18.90)
$75K+ (%) 58 (16.81) N/A N/A
Decline to answer (%) 16 (4.64) 27 (10.51) 33 (10.06)
Employed (%) 155 (44.93) 143 (55.64) 195 (59.45)
Retired (%) 65 (18.84) 35 (13.62) 40 (12.20)
Long-term disability (%) 51 (14.78) 23 (8.95) 24 (7.32)
Insured (%) 292 (84.64) N/A N/A
Body mass index
Underweight (%) 2 (0.58) 10 (3.89) 15 (4.57)
Normal weight (%) 133 (38.55) 109 (42.41) 141 (42.99)
Overweight (%) 87 (25.22) 81 (31.52) 101 (30.79)
Obese (%) 117 (33.91) 55 (21.40) 69 (21.04)
Decline to provide weight (%) 6 (1.74) 2 (0.78) 2 (0.61)
Consume alcohol (%) 182 (52.75) 175 (68.09) 217 (66.16)
Smoking behavior
Nonsmoker (%) 183 (53.04) 111 (43.19) 144 (43.90)
Former smoker (%) 87 (25.22) 71 (27.63) 95 (28.96)
Current smoker (%) 75 (21.74) 75 (29.18) 89 (27.13)
Exercise (%) 222 (64.35) 155 (60.31) 193 (58.84)
Charlson comorbidity index—mean  SD 0.85  2.20 0.82  2.39 0.85  2.30
Length of time diagnosed with epilepsy
0–5 years (%) 47 (13.62) 49 (19.07) 58 (17.68)
6–10 years (%) 47 (13.62) 32 (12.45) 35 (10.67)
11–15 years (%) 41 (11.88) 35 (13.62) 48 (14.63)
16–19 years (%) 26 (7.54) 18 (7.00) 22 (6.71)
20–30 years (%) 55 (15.94) 53 (20.62) 73 (22.26)
31 years or greater (%) 129 (37.39) 70 (27.24) 92 (28.05)
Using a prescription medication for epilepsy (%) 247 (71.59) 166 (64.59) 199 (60.67)
Total number of epilepsy prescriptions
None (%) 98 (28.41) 91 (35.41) 129 (39.33)
One medication (%) 146 (42.32) 115 (44.75) 137 (41.77)
Twomedications (%) 73 (21.16) 37 (14.40) 42 (12.80)
Three or more medications (%) 28 (8.12) 14 (5.45) 20 (6.10)
Antiepileptic medications (among those treating)
Acetazolamide (%) NR NR NR
Alprazolam (%) 0.00% 0.00% 1 (0.50)
Carbamazepine (%) 45 (18.22) 38 (22.89) 51 (25.63)
Clobazam (%) NR 3 (1.81) 3 (1.51)
Clonazepam (%) NR 6 (3.61) 8 (4.02)
Diazepam (%) NR NR NR
Eslicarbazepine (%) NR NR NR
Ethosuximide (%) NR NR NR
Felbamate (%) 0.00% 1 (0.60) 1 (0.50)
Gabapentin (%) 12 (4.86) 6 (3.61) 7 (3.52)
Gamibetal (%) NR NR NR
Lacosamide (%) 16 (6.48) 3 (1.81) 3 (1.51)
Lamotrigine (%) 66 (26.72) 35 (21.08) 42 (21.11)
Continued
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epilepsy patients were 49%U.S., 47%United Kingdom, 35%
Germany, 35% France, 27% Spain, 24% Italy, and 20% Bra-
zil. Physician-diagnosed estimates in the literature indicate
that IGE should be 16% of the epilepsy population.2 The pro-
portions reporting “Don’t Know” in the NHWS were 29%
U.S., 32% United Kingdom, 46% Germany, 39% France,
35% Spain, 29% Italy, and 38% Brazil. Thus, reported out-
comes may reflect a conservative or minimal estimate of the
burden experienced by FE patients if there is a higher propor-
tion of focal without SGSs in our FE population. A compari-
son with published epilepsy costs for the 5EU (adjusted for
inflation), do suggest that our 5EU cost estimates are within
range of individual country estimate (Table 5). The impact
on the cost estimates is difficult to estimate and ranges
between some country publications were fairly wide.
It is also interesting to note that the U.S. dataset had the
lowest FE proportion out of the datasets analyzed (possibly
the fewest FE with SGSs) and demonstrated a seizure fre-
quency association with outcomes in less than half of the
associations tested. The EU dataset had a mix of low (Uni-
ted Kingdom 29%) and higher (Italy 57%) FE proportions
and demonstrated an association with all but three outcomes
tested. Combining the Brazil (FE 66%) and 5EU datasets
resulted in showing an association with all outcomes tested.
The results appear to support the hypothesis that SGSs drive
more associations with seizure frequency and outcomes.
Self-reporting of seizure frequencies is the standard for
clinical trials. A limitation of this is that absence seizures
and seizures occurring during sleep may be underreported.
However, focal seizures and other generalized seizures
would be captured for all other time periods. Partial seizures
are often more frequent than SGSs and may quickly add to
the total seizure count, but SGSs may have a larger impact
on QoL, productivity, and HRU. This study did not collect
seizure frequency separately for each seizure type. How-
ever, as discussed earlier, the variation in FE proportion
across datasets (a proxy for SGS) provides insight into the
importance of SGSs in demonstrating an association
between seizure frequency and outcomes.
Epilepsy patient proportions reporting <1 seizure per year
were 44% (U.S.), 58% (5EU), and 59% (5EU + Brazil).
Data were not collected on total lifetime AED use; however,
these values are close to those reported in a prior study of
newly diagnosed patients showing seizure freedom rates of
49.5%with the first regimen and 13.3%with the second reg-
imen (total: 62.8% seizure free by second regimen).21 Thus,
NHWS percentages may be consistent with patients who
have tried fewer cumulative regimens. Conversely, NHWS
data indicate the following persistent seizures rates: 56%
(U.S.), 42% (5EU), and 41% (5EU + Brazil). These are
consistent with other research for epilepsy patients on
monotherapy regimens22 and patients treated with multiple
AEDs.23,24
Previous studies have demonstrated an association bet-
ween SF-36 domain scores and having any seizures.4,25–27
On the basis of pairwise comparisons, MCS results for all
three datasets are consistent with studies in patients with
uncontrolled seizures (studies lacking a seizure-free group)
that found no relationship between seizure frequency and
QoL,28–30 whereas PCS and health utility results for the
5EU and Brazil + 5EU datasets supported a relationship.
Differences in some of the results between this study and
others may result from the use of the SF-36v2. Interest-
ingly, studies that did not find an association used epi-
lepsy-specific QoL scales. The differences observed
between regions on the PCS and health utility results may
be due to the differences in regions in FE proportions (a
potential proxy for SGS).
Table 2. Continued.
U.S. values (N = 345) 5EU values (N = 257) Brazil + 5EU values (N = 328)
Levetiracetam (%) 73 (29.55) 37 (22.29) 37 (18.59)
Lorazepam (%) NR NR NR
Oxcarbazepine (%) 26 (10.53) 8 (4.82) 14 (7.04)
Perampanel (%) 1 (0.40) NR NR
Phenobarbital (%) NR 7 (4.22) 7 (3.52)
Phenytoin (%) 35 (14.17) 9 (5.42) 9 (4.52)
Pregabalin (%) 10 (4.05) 3 (1.81) 3 (1.51)
Primidone (%) NR NR NR
Retigabine (%) 1 (0.40) 1 (0.60) 1 (0.50)
Rufinamide (%) 5 (2.02) NR NR
Stiripentol (%) 0.00% 1 (0.60) 1 (0.50)
Tiagabine (%) 4 (1.62) 2 (1.20) 2 (1.01)
Topiramate (%) 30 (12.15) 17 (10.24) 23 (11.56)
Valproate (%) 28 (11.34) 26 (15.66) 30 (15.08)
Vigabatrin (%) 2 (0.81) 0.00% 0.00%
Zonisamide (%) 20 (8.10) 5 (3.01) 5 (2.51)
FE, focal epilepsy; N/A, not applicable because these data were not collected; NR, not reported.
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Of the productivity measures, the U.S. dataset pairwise
results did not support global tests for any of the measures
except indirect costs (ages 18–60). For presenteeism and
overall work impairment, global tests were significant, but
pairwise tests were not at the Bonferroni threshold. Pairwise
results in the 5EU dataset supported a relationship for activ-
ity impairment and indirect costs (ages 18–60). For the
Brazil + 5EU dataset, pairwise results supported a relation-
ship for absenteeism, overall work impairment, and activity
impairment. Again, the higher FE proportion (and likely
higher SGS proportion) in the Brazil + 5EU dataset may
explain why a greater number of associations were demon-
strated.
Of the HRU measures, pairwise results in the U.S.
dataset supported relationships between seizure fre-
quency with hospitalizations and direct costs. For the
5EU dataset, pairwise results supported relationships
with ER visits, hospitalizations, ER visit costs, and total
direct costs. For the Brazil + 5EU dataset, pairwise
results supported relationships with provider visits and
ER visits. Differences between regional datasets may be
reflective of differences in patterns of care between
regions. Unlike the other datasets, the U.S. dataset lacks
universal healthcare coverage. About 15% of the U.S.
dataset was uninsured, with the remaining covered by
Medicare, Medicaid (managed separately by each U.S.
state), Tricare (military), or a multitude of private insur-
ers that each offers hundreds of different coverage plans.
The other countries have universal or near universal
coverage, which is a mix of mostly government cover-
age and private coverage.
Because the NHWS is an Internet-based survey, results
may have been affected by selection bias. For example,
some FE patients in the three regions examined may have
had insufficient access to or experience with the requisite
technology. Additionally, those more severely affected by
their epilepsy seizures may have been more inclined to
report their epilepsy. Alternatively, respondents hospital-
ized or highly impaired because of their epilepsy may not
have been healthy enough to participate in the study. The
overall direction of this potential selection bias is uncertain.
Moreover, given that response rates for the NHWS varied
by region, we cannot exclude the possibility that the results
reflect cultural differences in the willingness to participate
or other unmeasured variables, rather than actual differ-
ences in the prevalence of FE. Surgical status, which may
influence patients’ physical and mental health status, as well
as epilepsy-related costs incurred, was not measured in this
study, thereby potentially reducing the validity of the find-
ings.
Causal inferences cannot be established because the data
were cross-sectional. The estimates of indirect costs must
be interpreted cautiously. Specifically, the small sample
sizes used to perform these analyses limited the statistical
power (i.e., very few respondents were employed and there
were a disproportionately smaller number of respondents in
the higher seizure frequency categories).
Conclusions
Overall, results from the current study highlight interest-
ing differences between regions on QoL associations that
may or may not be reflective of a higher or lower propor-
tion of SGS patients. This study also updated the under-
standing of how seizure frequency relates to productivity
and indirect costs and provided new findings about HRU
and direct costs. Whereas the relationship between seizure
frequency and QoL, productivity, and indirect costs may be
driven primarily by the difference between having seizures
and not having seizures in this and previous studies, it is
possible that larger datasets may demonstrate more refined
differences between seizure frequency categories. This par-
ticular study did demonstrate regional differences in the
association between seizure frequency and health resource
utilization. These differences may be reflective of differ-
ences in healthcare coverage between regions. Nearly, half
of the patients in this study had persistent seizures, despite
most taking at least one AED in this 2011–2013 dataset.
These results suggest that additional treatment options are
needed to both improve seizure control and reduce direct
costs.
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Table 5. Comparison of direct cost estimates by seizure frequency
Direct costs PPPY (2013 Euros) Current study Berto (Italy)6 De Zelicourt (France)7 Hamer (Germany)8 Jacoby (United Kingdom)9
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Monthly 1,431.71 2,389.59 1,954.38 3,500.37
Annual 1,140.02 1,307.48 485.40 1,893.65
None 689.25 470.96 371.84
PPPY, per patient per year.
Values from original papers were converted to 2013 euros using the health-specific and country-specific Harmonized Index of Consumer Prices for Italy, France,
and Germany and the health-specific United Kingdom Consumer Price Index (2001–2013) and overall Retail Prices Index (1993–2000).
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